Approval of Latest Medicine for Ovarian Cancer

Roche (Famous Pharmaceuticals) announced on 25th December, approval of it's new medicine, " Avastin (bevacizumab) by the European Union for treatment of Ovarian Cancer. When uses in combination with chemotherapy (carboplatin and paclitaxel) , it's being claimed to increase the life of a patient.

Hal Barron M.D., Chief Medical Officer and Head, Global Product Development said : 


"Today's approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years ...This is the fifth tumor type for which Avastin has been approved in Europe, making it one of the few biologic drugs indicated for multiple cancers."